Prior to this agreement BioWa and Lonza entered into a strategic research collaboration agreement combining Kyowa Hakko’s Potelligent technology with Lonza’s glutamine synthetase (GS) Gene Expression System.
This worldwide, non-exclusive umbrella research and license agreement enables Kyowa Hakko Group to use Lonza’s proprietary GS-System and the Potelligent technology as a platform for the production of antibodies and recombinant proteins being developed by Kyowa Hakko Group.
Nobuo Hanai, managing officer, head of pharmaceutical R&D Division of Kyowa Hakko, said: “We are excited about the combination of our Potelligent technology with Lonza’s GS Gene Expression System which has potential to strengthen Kyowa Hakko Group’s production system for biological drugs.”